Table 1C.

Demographics by EGFR amplification status across all stage IV or recurrent esophagogastric cases prospectively screened at U of C for anti-EGFR therapy between September 2014 and December 2016

CharacteristicEGFR amplifiedEGFR nonamplifiedP
Number of patients (%)8 (6)132 (94)< 2.2 × 10−16
Median age, y (range)61.5 (48–74)61.5 (19–91)0.68
Male sex, n (%)6 (75)95 (72)1
Disease site, n (%)
 Esophagus/GEJ5 (63)73 (55)1
 Gastric3 (38)59 (45)
Tumor grade, n (%)
 Well differentiated0 (0)4 (3)1
 Moderately differentiated2 (25)27 (20)
 Poorly differentiated6 (75)93 (70)
 Unknown0 (0)8 (6)
Stage at diagnosis, n (%)
 I0 (0)3 (2)0.79
 II0 (0)11 (8)
 III1 (13)29 (22)
 IV7 (88)88 (67)
 Unknown0 (0)1 (1)
HER2, n (%)
 Positive2 (25)29 (22)1
 Negative6 (75)90 (68)
 Equivocal0 (0)2 (2)
 Unknown0 (0)11 (8)
Race, n (%)
 Caucasian7 (88)91 (69)0.43
 African American0 (0)18 (14)
 Asian0 (0)14 (11)
Hispanic1 (13)9 (7)